STO · SPRINT.ST
Sprint Bioscience AB
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
Loading market information…
STO · NICA.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 04:01 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Nanologica AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 92.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nanologica AB (publ)’s next earnings report is currently expected on Nov 26, 2026, with estimated earnings per share of -SEK 0.03. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nanologica AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces. The company provides products for the analysis and purification of substances, with a focus on peptides drugs for the treatment of diabetes and obesity. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| SEK 10.75M |
| Q4 2024 | Feb 14, 2025 | -SEK 0.19-90.0% vs estimate | SEK 6.72M-44.04% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | -SEK 0.54-181.13% vs estimate | SEK 600.00K-96.69% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 3.50+SEK 0.06 (+1.74%)
Sprint Bioscience AB’s quoted price sits in the upper half of its reported 52-week range, 23.75% below the high.
SEK 13.00-SEK 2.85 (-17.98%)
Xbrane Biopharma AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 35.0% below the high.
SEK 0.37+SEK 0.05 (+15.94%)
Biovica International AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 39.18% below the high.
SEK 3.83+SEK 0.03 (+0.66%)
Active Biotech AB’s quoted price sits in the lower half of its reported 52-week range, 59.44% below the high.
SEK 3.67SEK 0.00 (0.0%)
Scandinavian ChemoTech AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 52.71% below the high.
SEK 1.57+SEK 0.01 (+0.32%)
Pila Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.4% below the high.
SEK 7.61+SEK 0.01 (+0.13%)
Vivesto AB’s quoted price sits in the lower half of its reported 52-week range, 72.12% below the high.
SEK 0.49-SEK 0.00 (-0.4%)
Biosergen AB’s quoted price sits in the lower half of its reported 52-week range, 99.02% below the high.
